Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-23-000023

President and CEO sold 28,433 shares at an average $29.28 ($832,515)

  • President and CEO acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Watts Ryan J. · President and CEO

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-02-09 Sale : show line 1 in the form −3,433 $30.59 $105,015 2,229,031 I
2023-02-10 Exercise or conversion : show line 2 in the form +25,000 $0.68 $17,000 2,254,031 I
2023-02-10 Sale : show line 3 in the form −25,000 $29.10 $727,500 2,229,031 I
Open-market sales · 28,433 sh · avg $29.28 · $832,515

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-02-10 Exercise or conversion : show line 4 in the form Stock Option (right to buy) −25,000 1,220,617 D
Loading xslF345X03/wf-form4_167633361457163.xml…